Completed
Ritonavir-boosted elvitegravir versus raltegravir
A Multicenter, randomized, double-blind, double-dummy, phase 3 study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL)
Learn MoreFilter By:
Completed
Extended release nevirapine QD in treatment-naïve (VERxVE study)
A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada™ in antiretroviral therapy naïve HIV-1 infected patients. (VERxVE study)(Trial number 1100.1486)
Learn MoreCompleted
Fosamprenavir and Ritonavir or Fosamprenavir Alone, in Pediatric Patients with HIV Infection
48-Week Study of GW433908 and Ritonavir or GW433908 Alone, Twice Daily in Pediatric Patients with HIV Infection.
Learn MoreCompleted
Completed
Phase II study of TNX-355 with optimized background therapy
A phase II, multicentre, randomized, double-blind, placebo-controlled, three-Arm study of the anti-CD4 monoclonal antibody TNX-355 with optimized background therapy in treatment-experienced subjects infected with HIV-1. (TNX-355.03)
Learn MoreCompleted
TMC125 Expanded access programme
Early access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options (TMC125-C214)
Learn MoreCompleted
Prospective Observational Epidemiologic Study of Maraviroc’s Safety (POEM)
An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.